NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase III∝ complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7128-7140

  Reghellin, V ^a   Donnici, L ^a   Fenu, S ^a   Berno, V ^a   Calabrese, V ^b   Pagani, M ^a   Abrignani, S ^a   Peri, F ^b   Francesco, R D ^a   Neddermann, P ^a  

^a Istituto Nazionale di Genetica Molecolare   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHOLESTEROL; NESBUVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PHOSPHATIDYLINOSITOL 4 KINASE III ALPHA; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHATIDYLINOSITOL KINASE; PROTEIN INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NS-5 PROTEIN, HEPATITIS C VIRUS; PHOSPHATIDYLINOSITOL 4-PHOSPHATE; PHOSPHATIDYLINOSITOL PHOSPHATE 4-KINASE; PHOSPHOTRANSFERASE; POLYPHOSPHOINOSITIDE; PROTEIN BINDING; VIRUS PROTEIN;

ARTICLE; CELL MEMBRANE; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHOLESTEROL SYNTHESIS; COMPLEX FORMATION; CONTROLLED STUDY; CROSS RESISTANCE; DENSITOMETRY; DOWN REGULATION; DRUG MECHANISM; EC50; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GENE SILENCING; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; INTRACELLULAR MEMBRANE; MEMBRANE; MEMBRANE FORMATION; PHENOTYPE; PROTEIN PHOSPHORYLATION; REPLICON; REPLICON CELL; RNA REPLICATION; VIRUS REPLICATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; HEPACIVIRUS; LIVER CELL; METABOLISM; PROTEIN TRANSPORT; TUMOR CELL LINE; ULTRASTRUCTURE; VIROLOGY;

ANTIVIRAL AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL MEMBRANE; CHOLESTEROL; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HEPACIVIRUS; HEPATOCYTES; HUMANS; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN BINDING; PROTEIN TRANSPORT; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84912117710     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03293-14     Document Type: Article

References (59)

1. Aghemo A, De Francesco R. 2013. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58:428-438. http://dx .doi.org/10.1002/hep.26371.
2. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, Jr, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi .org/10.1038/nature08960.
3. Conte I, Giuliano C, Ercolani C, Narjes F, Koch U, Rowley M, Altamura S, De Francesco R, Neddermann P, Migliaccio G, Stansfield I. 2009. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg. Med. Chem. Lett. 19:1779-1783. http://dx.doi.org/10.1016/j.bmcl.2009.01.066.
4. Lemm JA, O'Boyle D, Jr, Liu M, Nower PT, Colonno R, Deshpande MS, Snyder LB, Martin SW, St Laurent DR, Serrano-Wu MH, Romine JL, Meanwell NA, Gao M. 2010. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84:482-491. http://dx.doi.org/10.1128/JVI.01360-09.
5. Belda O, Targett-Adams P. 2012. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res. 170:1-14. http://dx.doi .org/10.1016/j.virusres.2012.09.007.
6. Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Jr, Colonno RJ, Gao M, Meanwell NA, Hamann LG. 2014. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J. Med. Chem. 57:2013-2032. http://dx.doi.org/10.1021/jm401836p.
7. Barakat KH, Anwar-Mohamed A, Tuszynski JA, Robins MJ, Tyrrell DL, Houghton M. A refined model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. J. Chem. Inf. Model., in press. http://dx.doi.org/10.1021 /ci400631n.
8. O'Boyle DR, Jr, Sun JH, Nower PT, Lemm JA, Fridell RA, Wang C, Romine JL, Belema M, Nguyen VN, St Laurent DR, Serrano-Wu M, Snyder LB, Meanwell NA, Langley DR, Gao M. 2013. Characterizations of HCV NS5A replication complex inhibitors. Virology 444:343-354. http://dx.doi.org/10.1016/j.virol.2013.06.032.
9. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83:4395-4403. http://dx.doi.org/10.1128/JVI.02352-08.
10. Tellinghuisen TL, Marcotrigiano J, Rice CM. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379. http://dx.doi.org/10.1038/nature03580.
11. Huang Y, Staschke K, De Francesco R, Tan SL. 2007. Phosphorylation of hepatitisCvirus NS5A nonstructural protein: a new paradigm for phos-phorylation-dependent viral RNA replication? Virology 364:1-9. http: //dx.doi.org/10.1016/j.virol.2007.01.042.
12. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. 2011. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85:7312-7320. http://dx.doi.org/10.1128/JVI.00253-11.
13. Ferraris P, Blanchard E, Roingeard P. 2010. Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes. J. Gen. Virol. 91:2230-2237. http://dx.doi.org/10.1099/vir.0.022186-0.
14. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, Moradpour D. 2003. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 77:5487-5492. http://dx.doi.org/10.1128/JVI.77.9.5487-5492.2003.
15. Miller S, Krijnse-Locker J. 2008. Modification of intracellular membrane structures for virus replication. Nat. Rev. Microbiol. 6:363-374. http://dx .doi.org/10.1038/nrmicro1890.
16. Paul D, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R. 2013. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J. Virol. 87:10612-10627. http: //dx.doi.org/10.1128/JVI.01370-13.
17. Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, Santarella-Mellwig R, Habermann A, Hoppe S, Kallis S, Walther P, Antony C, Krijnse-Locker J, Bartenschlager R. 2012. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. 8:e1003056. http://dx.doi.org/10 .1371/journal.ppat.1003056.
18. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106:7577-7582. http://dx.doi.org/10.1073 /pnas.0902693106.
19. Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Compton T, Labow M, Wiedmann B, Gaither LA. 2009. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 83:10058-10074. http://dx .doi.org/10.1128/JVI.02418-08.
20. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT. 2009. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5:298-307. http://dx.doi.org/10 .1016/j.chom.2009.02.001.
21. Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G. 2009. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 387:5-10. http://dx.doi.org/10.1016/j.virol.2009.02.039.
22. Lim YS, Hwang SB. 2011. Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J. Biol. Chem. 286:11290-11298. http://dx.doi.org/10.1074/jbc.M110 .194472.
23. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45. http://dx.doi.org/10.1016/j.chom.2010 .12.002.
24. Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G. 2011. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J. Virol. 85:8870-8883. http://dx.doi.org/10.1128/JVI.00059-11.
25. Tai AW, Salloum S. 2011. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One 6:e26300. http://dx.doi.org/10.1371/journal.pone.0026300.
26. Reiss S, Harak C, Romero-Brey I, Radujkovic D, Klein R, Ruggieri A, Rebhan I, Bartenschlager R, Lohmann V. 2013. The lipid kinase phos-phatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog. 9:e1003359. http://dx.doi.org/10 .1371/journal.ppat.1003359.
27. Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, Tai AW. 2014. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required forHCVreplication membrane integrity and cholesterol trafficking. Gastroenterology 146:1373-1385. http://dx.doi.org/10.1053/j .gastro.2014.02.002.
28. Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, Narjes F, Muraglia E, Paonessa G, Koch U, De Francesco R, Steinkuhler C, Migliaccio G. 2003. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77:3669-3679. http://dx.doi.org/10.1128/JVI.77.6.3669-3679 .2003.
29. Neddermann P, Quintavalle M, Di Pietro C, Clementi A, Cerretani M, Altamura S, Bartholomew L, De Francesco R. 2004. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J. Virol. 78: 13306-13314. http://dx.doi.org/10.1128/JVI.78.23.13306-13314.2004.
30. Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, Abrignani S, Neddermann P, De Francesco R. 2012. Metabolism of phosphatidylinositol 4-kinase III-dependent PI4P is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog. 8:e1002576. http://dx.doi.org/10.1371/journal.ppat.1002576.
31. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org /10.1053/j.gastro.2003.09.023.
32. Neddermann P, Clementi A, De Francesco R. 1999. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J. Virol. 73:9984-9991.
33. Pizzi E, Tramontano A, Tomei L, La Monica N, Failla C, Sardana M, Wood T, De Francesco R. 1994. Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc. Natl. Acad. Sci. U. S. A. 91:888-892. http://dx.doi.org/10.1073/pnas .91.3.888.
34. Schmitz U, Tan SL. 2008. NS5A-from obscurity to new target for HCV therapy. Recent Pat. Antiinfect. Drug Discov. 3:77-92. http://dx.doi.org /10.2174/157489108784746597.
35. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650. http://dx.doi.org /10.1128/AAC.00556-10.
36. Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DL, Immermann F, Chaudhary I, Speth J, Villano SA, O'Connell J, Collett M. 2009. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitisCvirus. Hepatology 49:745-752. http://dx.doi.org/10 .1002/hep.22717.
37. Qiu D, Lemm JA, O'Boyle DR, Jr, Sun JH, Nower PT, Nguyen V, Hamann LG, Snyder LB, Deon DH, Ruediger E, Meanwell NA, Belema M, Gao M, Fridell RA. 2011. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J. Gen. Virol. 92:2502-2511. http://dx.doi.org/10.1099/vir.0.034801-0.
38. Quintavalle M, Sambucini S, Di Pietro C, De Francesco R, Neddermann P. 2006. The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation. J. Virol. 80:11305-11312. http://dx.doi.org/10.1128/JVI.01465-06.
39. Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, Harak C, Hoppe S, Gao M, Penin F, Lohmann V, Bartenschlager R. Daclatasvir-like inhibitors of NS5A block early biogenesis of HCVinduced membranous replication factories, independent of RNA replication. Gastroenterology, in press. http://dx.doi.org/10.1053/j.gastro.2014 .07.019.
40. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76:5974-5984. http://dx.doi.org/10.1128/JVI.76.12.5974-5984.2002.
41. Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, Brain P, Tran TD, Jones LH, Wakenhut F, Stammen B, Pryde D, Pickford C, Westby M. 2011. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J. Virol. 85:6353-6368. http://dx .doi.org/10.1128/JVI.00215-11.
42. Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, Elazar M, Klumpp K, Glenn JS. 2011. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414:10-18. http://dx.doi.org/10.1016/j.virol.2011.03.026.
43. McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, De Francesco R, Howe AY, Lemon SM. 2014. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147:453-462.e7. http://dx.doi.org/10.1053/j.gastro.2014.04.021.
44. Lin C, Kwong AD, Perni RB. 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 6:3-16. http://dx.doi .org/10.2174/187152606776056706.
45. Hammond GR, Schiavo G, Irvine RF. 2009. Immunocytochemical techniques reveal multiple, distinct cellular pools of PtdIns4P and PtdIns(4,5)P(2). Biochem. J. 422:23-35. http://dx.doi.org/10.1042/BJ20090428.
46. Shi ST, Lee KJ, Aizaki H, Hwang SB, Lai MM. 2003. Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J. Virol. 77:4160-4168. http://dx.doi.org/10 .1128/JVI.77.7.4160-4168.2003.
47. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. 2004. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324:450-461. http://dx.doi.org/10.1016/j.virol.2004.03.034.
48. Alvisi G, Madan V, Bartenschlager R. 2011. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol. 8:258-269. http://dx.doi .org/10.4161/rna.8.2.15011.
49. Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG, Pagano RE, McMurray CT. 2006. Mutant huntingtin inhibits clathrinindependent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum. Mol. Genet. 15:3578-3591. http://dx.doi.org/10.1093 /hmg/ddl434.
50. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. 2013. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. U. S. A. 110:3991-3996. http://dx.doi.org/10.1073/pnas.1203110110.
51. Gao M. 2013. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr. Opin. Virol. 3:514-520. http://dx.doi.org/10 .1016/j.coviro.2013.06.014.
52. Belema M, Lopez OD, Bender JA, Romine JL, St Laurent DR, Langley DR, Lemm JA, O'Boyle DR, Jr, Sun JH, Wang C, Fridell RA, Meanwell NA. 2014. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J. Med. Chem. 57:1643-1672. http://dx.doi.org /10.1021/jm401793m.
53. Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJ, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811. http://dx.doi.org/10.1016/j.cell.2010.03.050.
54. D'Angelo G, Vicinanza M, Di Campli A, De Matteis MA. 2008. The multiple roles of PtdIns(4)P: not just the precursor of PtdIns(4,5)P2. J. Cell Sci. 121:1955-1963. http://dx.doi.org/10.1242/jcs.023630.
55. Kim YJ, Hernandez ML, Balla T. 2013. Inositol lipid regulation of lipid transfer in specialized membrane domains. Trends Cell Biol. 23:270-278. http://dx.doi.org/10.1016/j.tcb.2013.01.009.
56. Amako Y, Sarkeshik A, Hotta H, Yates J, III, Siddiqui A. 2009. Role of oxysterol binding protein in hepatitis C virus infection. J. Virol. 83:9237-9246. http://dx.doi.org/10.1128/JVI.00958-09.
57. Amako Y, Syed GH, Siddiqui A. 2011. Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxys-terol-binding protein and ceramide transfer protein. J. Biol. Chem. 286: 11265-11274. http://dx.doi.org/10.1074/jbc.M110.182097.
58. Park IW, Ndjomou J, Wen Y, Liu Z, Ridgway ND, Kao CC, He JJ. 2013. Inhibition of HCV replication by oxysterol-binding protein-related protein 4 (ORP4) through interaction with HCV NS5B and alteration of lipid droplet formation. PLoS One 8:e75648. http://dx.doi.org/10.1371/journal .pone.0075648.
59. Arita M. 2014. Phosphatidylinositol-4 kinase III beta and oxysterolbinding protein accumulate unesterified cholesterol on poliovirusinduced membrane structure. Microbiol. Immunol. 58:239-256. http: //dx.doi.org/10.1111/1348-0421.12144.